Important: By clicking “Yes” you are confirming that you are a healthcare professional. OncosilTM is currently unapproved for commercial sale in your region. If you are not a healthcare professional then please click here to Go to the Homepage.
OncoSil™ & Adjuvant Chemotherapy
OncoSil™ is an adjuvant therapy indicated for the treatment of patients with advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under Endoscopic Ultrasound (EUS) guidance.
Current Pancreatic Cancer Treatment with Adjuvant Chemotherapy
Current treatment options for patients with pancreatic cancer include Surgery, External radiation therapy, Chemotherapy, Chemo-radiation therapy¹
Chemotherapy is the current standard therapy for the treatment of locally advanced, unresectable or metastatic pancreatic cancer. Generally this involves treatment with chemotherapy agents as an individual treatment or combination therapy. First line regimens include gemcitabine alone, gemcitabine with nab-paclitaxel and FOLFIRINOX.
Previous studies of OncoSil™ in patients with pancreatic cancer were conducted in combination with gemcitabine.